SCHEMBL1114697

SCHEMBL1114697

CCCCCCCCCC(C)(C)CC(=O)O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.83
FFAR1 O14842 2/20 0.83
CPT2 P23786 1/20 0.83
GPR84 Q9NQS5 7/20 0.48
PPARG P37231 7/20 0.48
PPARD Q03181 7/20 0.48
PPARA Q07869 7/20 0.48
HDAC11 Q96DB2 5/20 0.48
TSHR P16473 4/20 0.48
PTPN1 P18031 3/20 0.48
ALDH1A1 P00352 2/20 0.48
TLR2 O60603 2/20 0.48
FABP4 P15090 2/20 0.48
SLC22A6 Q4U2R8 1/20 0.48
SLC22A8 Q8TCC7 1/20 0.48
MEN1 O00255 1/20 0.48
ESR1 P03372 1/20 0.48
ALOX15 P16050 1/20 0.48
PDE4A P27815 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27542041 1.00 TDP1 (0.83) TDP1FFAR1CPT2GPR84PPARG
SCHEMBL12451279 1.00 TDP1 (0.83) TDP1FFAR1CPT2GPR84PPARG
SCHEMBL3623870 1.00 TDP1 (0.83) TDP1FFAR1CPT2GPR84PPARG
SCHEMBL1873452 1.00 TDP1 (0.83) TDP1FFAR1CPT2GPR84PPARG
SCHEMBL742996 1.00 TDP1 (0.83) TDP1FFAR1CPT2GPR84PPARG
SCHEMBL20184209 1.00 TDP1 (0.83) TDP1FFAR1CPT2GPR84PPARG
SCHEMBL5878804 1.00 TDP1 (0.83) TDP1FFAR1CPT2GPR84PPARG
SCHEMBL22748728 1.00 TDP1 (0.83) TDP1FFAR1CPT2GPR84PPARG
SCHEMBL22748689 1.00 TDP1 (0.83) TDP1FFAR1CPT2GPR84PPARG
Hydrochloric Acid SCHEMBL8110283 0.98 TDP1 (0.79) TDP1FFAR1CPT2GPR84PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11796725-B2 Metal oxide microparticles, method for producing same, dispersion for forming infrared-shielding film, method for producing same, method for forming infrared-shielding film, and base material having infrared-shielding film MITSUBISHI MATERIALS CORPORATION (JP) 2023-10-24 US claimed
EP-2279741-A2 Caprolactams and their use as anti-inflammatory agents Cambridge Enterprise Ltd. (GB) 2011-02-02 EP claimed
US-20080227724-A1 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) 2008-09-18 US claimed
EP-1691814-A2 ANTI-INFLAMMATORY AGENTS CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) 2006-08-23 EP claimed
WO-2005053702-A2 ANTI-INFLAMMATORY AGENTS CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) 2005-06-16 WO claimed
US-11796725-B2 Metal oxide microparticles, method for producing same, dispersion for forming infrared-shielding film, method for producing same, method for forming infrared-shielding film, and base material having infrared-shielding film MITSUBISHI MATERIALS CORPORATION (JP) 2023-10-24 US disclosed
US-20210220328-A1 PYRROLE DERIVATIVES AS ACC INHIBITORS ALMIRALL SA (ES) 2021-07-22 US disclosed
US-20210191016-A1 METAL OXIDE MICROPARTICLES, METHOD FOR PRODUCING SAME, DISPERSION FOR FORMING INFRARED-SHIELDING FILM, METHOD FOR PRODUCING SAME, METHOD FOR PRODUCING SAME, METHOD FOR FORMING INFRARED-SHIELDING FILM, AND BASE MATERIAL HAVING INFRARED-SHIELDING FILM MITSUBISHI MATERIALS CORPORATION (JP) 2021-06-24 US disclosed
EP-3770119-A1 METAL OXIDE MICROPARTICLES, METHOD FOR PRODUCING SAME, DISPERSION FOR FORMING INFRARED-SHIELDING FILM, METHOD FOR PRODUCING SAME, METHOD FOR FORMING INFRARED-SHIELDING FILM, AND BASE MATERIAL HAVING INFRARED-SHIELDING FILM Mitsubishi Materials Corporation (JP) 2021-01-27 EP disclosed
CN-111886230-A Pyrrole derivatives as ACC inhibitors 阿尔米雷尔有限公司 2020-11-03 CN disclosed
EP-3724182-A1 PYRROLE DERIVATIVES AS ACC INHIBITORS Almirall S.A. (ES) 2020-10-21 EP disclosed
WO-2019115405-A1 PYRROLE DERIVATIVES AS ACC INHIBITORS ALMIRALL, S.A. (ES) 2019-06-20 WO disclosed
CN-103393691-A Anti-inflammatory agents UNIV CAMBRIDGE TECH 2013-11-20 CN disclosed
EP-1691814-B9 ANTI-INFLAMMATORY AGENTS CAMBRIDGE ENTPR LTD (GB) 2013-02-20 EP disclosed
EP-1691814-B1 ANTI-INFLAMMATORY AGENTS CAMBRIDGE ENTPR LTD (GB) 2012-07-25 EP disclosed
EP-2279741-A2 Caprolactams and their use as anti-inflammatory agents Cambridge Enterprise Ltd. (GB) 2011-02-02 EP disclosed
US-20080227724-A1 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) 2008-09-18 US disclosed
CN-1897953-A Anti-inflammatory agents UNIV CAMBRIDGE TECH (GB) 2007-01-17 CN disclosed
EP-1691814-A2 ANTI-INFLAMMATORY AGENTS CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) 2006-08-23 EP disclosed
WO-2005053702-A2 ANTI-INFLAMMATORY AGENTS CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227724-A1 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents SMURF1, SMURF2, PSEN1 TDP1 1627/4885FFAR1 177/4885CPT2 292/4885
US-20210220328-A1 PYRROLE DERIVATIVES AS ACC INHIBITORS ACACA, ACACB, PCCA TDP1 3503/4885FFAR1 3053/4885CPT2 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.